“A
common steroid drug that's been used for decades to treat conditions from
altitude sickness to eye inflammation has been shown to reduce deaths by a
third in the sickest patients in the hospital with COVID-19, British scientists
say. This is the first time, the researchers say, that a drug has been shown to
have an effect on deaths rates of the virus that's killed more than 110,000
people in the U.S.
“Researchers
at the University of Oxford in the U.K. compared outcomes of 2,104 hospitalized
patients who received the steroid, called dexamethasone, with 4,321 patients
who did not. According to the researchers, deaths were reduced by about a third
in those patients who were sick enough to require mechanical ventilation, and
by about 20 percent among patients who had trouble breathing, but had not been
put on a ventilator. Dexamethasone did not appear to help patients who did not
require oxygen.
“The
results of the clinical trial, called RECOVERY,
have not yet been published in a medical journal and the data have not been
made available for outside experts to review. Researchers said they stopped the
trial early because of the observed benefits.
“Dr.
Ashish Jha, director of the Harvard Global Health Institute, expressed
frustration on Twitter that ‘it is now a feature of this pandemic that most
findings made public via press release with little data to provide context.’
But, he added, ‘this is REALLY good news if it turns out to be true.’
“‘The
survival benefit is clear and large in those patients who are sick enough to
require oxygen treatment,’ Dr. Peter Horby, one of the RECOVERY study
researchers and a professor at the University of Oxford, said in a press
release. 'Dexamethasone is inexpensive, on the shelf, and can be used
immediately to save lives worldwide.'
“Outside experts called the results important and promising, but
added the full data should be released for a complete analysis of how it worked
in this clinical trial. ‘The low cost and broad availability of this drug means
that there is potential for considerable clinical impact by including it as
part of standard treatment,’ Dr. Stephen Griffin, an associate professor of
medicine at the UK's University of Leeds, said in a statement. Griffin was not
involved with the trial.
“‘Nevertheless,
it will be important to assess how this important success might be further
improved in order to increase patient survival, perhaps through the combination
of low-dose dexamethasone with other inflammatory mediators, or with
virus-targeted therapies, such as remdesivir,’ Griffin said.
“Remdesivir is the
only other therapy that's been shown in a clinical trial to help coronavirus
patients. Results of that trial found that hospitalized patients who received
the drug recovered more quickly and were able to be released from the hospital
faster. It did not affect mortality, though” (NBC).
This is a developing story.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.